GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (OTCPK:GIKLY) » Definitions » Beneish M-Score

GIKLY (Grifols) Beneish M-Score : -2.26 (As of Dec. 13, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Grifols Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.26 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Grifols's Beneish M-Score or its related term are showing as below:

GIKLY' s Beneish M-Score Range Over the Past 10 Years
Min: -4.34   Med: -2.48   Max: -1.37
Current: -2.26

During the past 13 years, the highest Beneish M-Score of Grifols was -1.37. The lowest was -4.34. And the median was -2.48.


Grifols Beneish M-Score Historical Data

The historical data trend for Grifols's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Beneish M-Score Chart

Grifols Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.73 -2.44 -2.63 -2.04 -

Grifols Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.55 -2.00 - -2.65 -2.26

Competitive Comparison of Grifols's Beneish M-Score

For the Drug Manufacturers - General subindustry, Grifols's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Grifols's Beneish M-Score falls into.



Grifols Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Grifols for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.065+0.528 * 0.9267+0.404 * 0.9302+0.892 * 1.1193+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.9481+4.679 * 0.008807-0.327 * 0.2061
=-2.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Jun23) TTM:
Total Receivables was $1,118 Mil.
Revenue was 1989.962 + 1956.843 + 1929.716 + 1704.889 = $7,581 Mil.
Gross Profit was 806.609 + 721.682 + 766.42 + 674.315 = $2,969 Mil.
Total Current Assets was $5,908 Mil.
Total Assets was $22,512 Mil.
Property, Plant and Equipment(Net PPE) was $3,510 Mil.
Depreciation, Depletion and Amortization(DDA) was $0 Mil.
Selling, General, & Admin. Expense(SGA) was $1,279 Mil.
Total Current Liabilities was $2,614 Mil.
Long-Term Debt & Capital Lease Obligation was $0 Mil.
Net Income was 57.371 + 15.975 + 80.195 + 63.546 = $217 Mil.
Non Operating Income was -2.686 + 38.716 + -12.238 + -4.974 = $19 Mil.
Cash Flow from Operations was 0 + 0 + 0 + 0 = $0 Mil.
Total Receivables was $938 Mil.
Revenue was 1802.23 + 1814.349 + 1525.871 + 1630.971 = $6,773 Mil.
Gross Profit was 658.358 + 634.649 + 554.327 + 610.941 = $2,458 Mil.
Total Current Assets was $5,206 Mil.
Total Assets was $23,221 Mil.
Property, Plant and Equipment(Net PPE) was $3,495 Mil.
Depreciation, Depletion and Amortization(DDA) was $0 Mil.
Selling, General, & Admin. Expense(SGA) was $586 Mil.
Total Current Liabilities was $2,034 Mil.
Long-Term Debt & Capital Lease Obligation was $11,054 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1118.05 / 7581.41) / (937.928 / 6773.421)
=0.147473 / 0.138472
=1.065

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2458.275 / 6773.421) / (2969.026 / 7581.41)
=0.36293 / 0.391619
=0.9267

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (5908.172 + 3509.921) / 22512.368) / (1 - (5205.603 + 3494.782) / 23220.741)
=0.581648 / 0.625318
=0.9302

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=7581.41 / 6773.421
=1.1193

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 3494.782)) / (0 / (0 + 3509.921))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1278.617 / 7581.41) / (586.392 / 6773.421)
=0.168652 / 0.086573
=1.9481

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 2614.401) / 22512.368) / ((11053.724 + 2033.569) / 23220.741)
=0.116132 / 0.563604
=0.2061

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(217.087 - 18.818 - 0) / 22512.368
=0.008807

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Grifols has a M-score of -2.24 suggests that the company is unlikely to be a manipulator.


Grifols Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Grifols's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols Business Description

Address
Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.